RESTful Lookup — Test-Drive (2007 – 2026)

{
  "NDC": [
    {
      "NDCCode": "75857-2150-8",
      "PackageDescription": "8 mL in 1 BOTTLE (75857-2150-8)",
      "NDC11Code": "75857-2150-08",
      "ProductNDC": "75857-2150",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Spf 15 Sunscreen",
      "NonProprietaryName": "Octinoxate, Oxybenzone, Octisalate, Titanium Dioxide",
      "DosageFormName": "LOTION",
      "RouteName": "TOPICAL",
      "StartMarketingDate": "20130918",
      "MarketingCategoryName": "OTC MONOGRAPH NOT FINAL",
      "ApplicationNumber": "part352",
      "LabelerName": "Ningbo Dowland Daily Health Co., Ltd",
      "SubstanceName": "OCTINOXATE; OXYBENZONE; OCTISALATE; TITANIUM DIOXIDE",
      "StrengthNumber": "50; 15; 10; 20",
      "StrengthUnit": "mg/mL; mg/mL; mg/mL; mg/mL",
      "Status": "Deprecated",
      "LastUpdate": "2017-02-13"
    },
    {
      "NDCCode": "75857-1100-8",
      "PackageDescription": "8 mL in 1 BOTTLE (75857-1100-8)",
      "NDC11Code": "75857-1100-08",
      "ProductNDC": "75857-1100",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Antibactierial Hand Sanitizer",
      "NonProprietaryName": "Ethyl Alcohol",
      "DosageFormName": "LIQUID",
      "RouteName": "ORAL",
      "StartMarketingDate": "20130201",
      "MarketingCategoryName": "OTC MONOGRAPH NOT FINAL",
      "ApplicationNumber": "part333E",
      "LabelerName": "Ningbo Dowland Daily Health Co., Ltd",
      "SubstanceName": "ALCOHOL",
      "StrengthNumber": "62",
      "StrengthUnit": "mL/100mL",
      "Status": "Deprecated",
      "LastUpdate": "2017-02-07"
    },
    {
      "NDCCode": "75857-1105-8",
      "PackageDescription": "58 mL in 1 BOTTLE (75857-1105-8)",
      "NDC11Code": "75857-1105-08",
      "ProductNDC": "75857-1105",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Antibactierial Hand Sanitizer",
      "NonProprietaryName": "Ethyl Alcohol",
      "DosageFormName": "LIQUID",
      "RouteName": "ORAL",
      "StartMarketingDate": "20130201",
      "MarketingCategoryName": "OTC MONOGRAPH NOT FINAL",
      "ApplicationNumber": "part333E",
      "LabelerName": "Ningbo Dowland Daily Health Co., Ltd",
      "SubstanceName": "ALCOHOL",
      "StrengthNumber": "62",
      "StrengthUnit": "mL/100mL",
      "Status": "Deprecated",
      "LastUpdate": "2017-02-07"
    },
    {
      "NDCCode": "75857-1108-8",
      "PackageDescription": "88 mL in 1 BOTTLE (75857-1108-8)",
      "NDC11Code": "75857-1108-08",
      "ProductNDC": "75857-1108",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Antibacterial Hand Sanitizer",
      "NonProprietaryName": "Ethyl Alcohol",
      "DosageFormName": "GEL",
      "RouteName": "TOPICAL",
      "StartMarketingDate": "20131211",
      "MarketingCategoryName": "OTC MONOGRAPH NOT FINAL",
      "ApplicationNumber": "part333E",
      "LabelerName": "Ningbo Dowland Daily Health Co., Ltd",
      "SubstanceName": "ALCOHOL",
      "StrengthNumber": "62",
      "StrengthUnit": "mL/100mL",
      "Status": "Deprecated",
      "LastUpdate": "2017-02-07"
    },
    {
      "NDCCode": "75857-2101-8",
      "PackageDescription": "1 TUBE in 1 BOX (75857-2101-8)  > 18 g in 1 TUBE",
      "NDC11Code": "75857-2101-08",
      "ProductNDC": "75857-2101",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Spf30 Sunscreen",
      "NonProprietaryName": "Octocrylene, Octinoxate, Oxybenzone, Oxybenzone",
      "DosageFormName": "STICK",
      "RouteName": "TOPICAL",
      "StartMarketingDate": "20151223",
      "MarketingCategoryName": "OTC MONOGRAPH NOT FINAL",
      "ApplicationNumber": "part352",
      "LabelerName": "Ningbo Dowland Daily Health Co., Ltd",
      "SubstanceName": "OCTOCRYLENE; OCTINOXATE; OXYBENZONE; AVOBENZONE",
      "StrengthNumber": "8; 7.5; 3; 1.5",
      "StrengthUnit": "mg/g; mg/g; mg/g; mg/g",
      "Status": "Deprecated",
      "LastUpdate": "2017-02-07"
    },
    {
      "NDCCode": "75857-9300-8",
      "PackageDescription": "236 mL in 1 BOTTLE (75857-9300-8)",
      "NDC11Code": "75857-9300-08",
      "ProductNDC": "75857-9300",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Spf 30 Sunscreen",
      "NonProprietaryName": "Octinoxate, Octisalate, Oxybenzone, Titanium Dioxide",
      "DosageFormName": "LOTION",
      "RouteName": "TOPICAL",
      "StartMarketingDate": "20140108",
      "MarketingCategoryName": "OTC MONOGRAPH NOT FINAL",
      "ApplicationNumber": "part352",
      "LabelerName": "Ningbo Dowland Daily Health Co., Ltd",
      "SubstanceName": "OCTINOXATE; OCTISALATE; OXYBENZONE; TITANIUM DIOXIDE",
      "StrengthNumber": "75; 20; 40; 25",
      "StrengthUnit": "mg/mL; mg/mL; mg/mL; mg/mL",
      "Status": "Deprecated",
      "LastUpdate": "2017-02-07"
    },
    {
      "NDCCode": "0069-2150-30",
      "PackageDescription": "30 TABLET, FILM COATED in 1 BOTTLE (0069-2150-30) ",
      "NDC11Code": "00069-2150-30",
      "ProductNDC": "0069-2150",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Caduet",
      "NonProprietaryName": "Amlodipine Besylate And Atorvastatin Calcium",
      "DosageFormName": "TABLET, FILM COATED",
      "RouteName": "ORAL",
      "StartMarketingDate": "20040130",
      "MarketingCategoryName": "NDA",
      "ApplicationNumber": "NDA021540",
      "LabelerName": "Pfizer Laboratories Div Pfizer Inc",
      "SubstanceName": "AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM TRIHYDRATE",
      "StrengthNumber": "5; 10",
      "StrengthUnit": "mg/1; mg/1",
      "Pharm_Classes": "Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS], HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]",
      "Status": "Deprecated",
      "LastUpdate": "2024-04-09",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20241231",
      "StartMarketingDatePackage": "20040130",
      "SamplePackage": "N",
      "IndicationAndUsage": "CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate.",
      "Description": "CADUET (amlodipine and atorvastatin) tablets combine the calcium channel blocker amlodipine besylate with the HMG CoA-reductase inhibitor atorvastatin calcium. Amlodipine besylate is chemically described as 3-ethyl-5-methyl (±)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate, monobenzenesulphonate. Its empirical formula is C20H25ClN2O5∙C6H6O3S. Atorvastatin calcium is chemically described as [R-(R*, R*)]-2-(4-fluorophenyl)-ß, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, calcium salt (2:1) trihydrate. Its empirical formula is (C33H34 FN2O5)2Ca∙3H2O. The structural formulae for amlodipine besylate and atorvastatin calcium are shown below. CADUET contains amlodipine besylate, a white to off-white crystalline powder, and atorvastatin calcium, also a white to off-white crystalline powder. Amlodipine besylate has a molecular weight of 567.1 and atorvastatin calcium has a molecular weight of 1209.42. Amlodipine besylate is slightly soluble in water and sparingly soluble in ethanol. Atorvastatin calcium is insoluble in aqueous solutions of pH 4 and below. Atorvastatin calcium is very slightly soluble in distilled water, pH 7.4 phosphate buffer, and acetonitrile; slightly soluble in ethanol; and freely soluble in methanol. CADUET is available as film-coated tablets containing: 1 5 mg amlodipine equivalent to 6.9 mg amlodipine besylate and 10 mg atorvastatin equivalent to 10.4 mg atorvastatin calcium., 2 5 mg amlodipine equivalent to 6.9 mg amlodipine besylate and 20 mg atorvastatin equivalent to 20.7 mg atorvastatin calcium., 3  5 mg amlodipine equivalent to 6.9 mg amlodipine besylate and 40 mg atorvastatin equivalent to 41.4 mg atorvastatin calcium., 4 5 mg amlodipine equivalent to 6.9 mg amlodipine besylate and 80 mg atorvastatin equivalent to 82.9 mg atorvastatin calcium., 5 10 mg amlodipine equivalent to 13.9 mg amlodipine besylate and 10 mg atorvastatin equivalent to 10.4 mg atorvastatin calcium., 6 10 mg amlodipine equivalent to 13.9 mg amlodipine besylate and 20 mg atorvastatin equivalent to 20.7 mg atorvastatin calcium., 7 10 mg amlodipine equivalent to 13.9 mg amlodipine besylate and 40 mg atorvastatin equivalent to 41.4 mg atorvastatin calcium., 8 10 mg amlodipine equivalent to 13.9 mg amlodipine besylate and 80 mg atorvastatin equivalent to 82.9 mg atorvastatin calcium."
    },
    {
      "NDCCode": "63874-201-01",
      "PackageDescription": "100 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (63874-201-01)",
      "NDC11Code": "63874-0201-01",
      "ProductNDC": "63874-201",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Propoxyphene And Acetaminophen",
      "NonProprietaryName": "Propoxyphene Napsylate And Acetaminophen",
      "DosageFormName": "TABLET, FILM COATED",
      "RouteName": "ORAL",
      "StartMarketingDate": "20100101",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA074843",
      "LabelerName": "Altura Pharmaceuticals, Inc.",
      "SubstanceName": "PROPOXYPHENE NAPSYLATE; ACETAMINOPHEN",
      "StrengthNumber": "100; 650",
      "StrengthUnit": "mg/1; mg/1",
      "Pharm_Classes": "Full Opioid Agonists [MoA],Opioid Agonist [EPC]",
      "DEASchedule": "CIV",
      "Status": "Deprecated",
      "LastUpdate": "2018-01-10",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "Propoxyphene napsylate and acetaminophen tablets, USP are indicated for the relief of mild to moderate pain.",
      "Description": "Propoxyphene Napsylate, USP is an odorless, white crystalline powder with a bitter taste. It is very slightly soluble in water and soluble in methanol, ethanol, chloroform, and acetone. Chemically, it is (αS,1R)-α-[2-(Dimethylamino)-1-methylethyl]-α-phenylphenethyl propionate compound with 2-napthalenesulfonic acid (1:1) monohydrate, which can be represented by the accompanying structural formula. Propoxyphene napsylate differs from propoxyphene hydrochloride in that it allows more stable liquid dosage forms and tablet formulations. Because of differences in molecular weight, a dose of 100 mg (176.8 μmol) of propoxyphene napsylate is required to supply an amount of propoxyphene equivalent to that present in 65 mg (172.9 μmol) of propoxyphene hydrochloride. Acetaminophen, 4'-hydroxyacetanilide, is a non-opiate, non-salicylate analgesic and antipyretic which occurs as a white, odorless, crystalline powder, possessing a slightly bitter taste. The molecular formula for acetaminophen is C8H9NO2 and the molecular weight is 151.16. It may be represented by the following structural formula. Propoxyphene Napsylate and Acetaminophen Tablets, USP 50 mg/325 mgEach tablet contains:       Propoxyphene Napsylate ............................50 mg (88.4 μmol)       Acetaminophen .........................................325 mg (2150 μmol) In addition each tablet contains the following inactive ingredients: carnauba wax, D&C Yellow #10 Aluminum Lake, FD&C Red #40 Aluminum Lake, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, polysorbate 80, sodium starch glycolate and titanium dioxide. Propoxyphene Napsylate and Acetaminophen Tablets, USP 100 mg/650 mgEach tablet contains:       Propoxyphene Napsylate ...........................100 mg (176.8 μmol)       Acetaminophen ..........................................650 mg (4300 μmol)In addition each tablet contains the following inactive ingredients: carnauba wax, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, polysorbate 80, sodium starch glycolate and titanium dioxide. The orange tablets also contain D&C Yellow #10 Aluminum Lake and FD&C Red #40 Aluminum Lake. The pink tablets also contain FD&C Red #40 Aluminum Lake."
    },
    {
      "NDCCode": "63874-201-04",
      "PackageDescription": "120 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (63874-201-04)",
      "NDC11Code": "63874-0201-04",
      "ProductNDC": "63874-201",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Propoxyphene And Acetaminophen",
      "NonProprietaryName": "Propoxyphene Napsylate And Acetaminophen",
      "DosageFormName": "TABLET, FILM COATED",
      "RouteName": "ORAL",
      "StartMarketingDate": "20100101",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA074843",
      "LabelerName": "Altura Pharmaceuticals, Inc.",
      "SubstanceName": "PROPOXYPHENE NAPSYLATE; ACETAMINOPHEN",
      "StrengthNumber": "100; 650",
      "StrengthUnit": "mg/1; mg/1",
      "Pharm_Classes": "Full Opioid Agonists [MoA],Opioid Agonist [EPC]",
      "DEASchedule": "CIV",
      "Status": "Deprecated",
      "LastUpdate": "2018-01-10",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "Propoxyphene napsylate and acetaminophen tablets, USP are indicated for the relief of mild to moderate pain.",
      "Description": "Propoxyphene Napsylate, USP is an odorless, white crystalline powder with a bitter taste. It is very slightly soluble in water and soluble in methanol, ethanol, chloroform, and acetone. Chemically, it is (αS,1R)-α-[2-(Dimethylamino)-1-methylethyl]-α-phenylphenethyl propionate compound with 2-napthalenesulfonic acid (1:1) monohydrate, which can be represented by the accompanying structural formula. Propoxyphene napsylate differs from propoxyphene hydrochloride in that it allows more stable liquid dosage forms and tablet formulations. Because of differences in molecular weight, a dose of 100 mg (176.8 μmol) of propoxyphene napsylate is required to supply an amount of propoxyphene equivalent to that present in 65 mg (172.9 μmol) of propoxyphene hydrochloride. Acetaminophen, 4'-hydroxyacetanilide, is a non-opiate, non-salicylate analgesic and antipyretic which occurs as a white, odorless, crystalline powder, possessing a slightly bitter taste. The molecular formula for acetaminophen is C8H9NO2 and the molecular weight is 151.16. It may be represented by the following structural formula. Propoxyphene Napsylate and Acetaminophen Tablets, USP 50 mg/325 mgEach tablet contains:       Propoxyphene Napsylate ............................50 mg (88.4 μmol)       Acetaminophen .........................................325 mg (2150 μmol) In addition each tablet contains the following inactive ingredients: carnauba wax, D&C Yellow #10 Aluminum Lake, FD&C Red #40 Aluminum Lake, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, polysorbate 80, sodium starch glycolate and titanium dioxide. Propoxyphene Napsylate and Acetaminophen Tablets, USP 100 mg/650 mgEach tablet contains:       Propoxyphene Napsylate ...........................100 mg (176.8 μmol)       Acetaminophen ..........................................650 mg (4300 μmol)In addition each tablet contains the following inactive ingredients: carnauba wax, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, polysorbate 80, sodium starch glycolate and titanium dioxide. The orange tablets also contain D&C Yellow #10 Aluminum Lake and FD&C Red #40 Aluminum Lake. The pink tablets also contain FD&C Red #40 Aluminum Lake."
    },
    {
      "NDCCode": "63874-201-30",
      "PackageDescription": "30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (63874-201-30)",
      "NDC11Code": "63874-0201-30",
      "ProductNDC": "63874-201",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Propoxyphene And Acetaminophen",
      "NonProprietaryName": "Propoxyphene Napsylate And Acetaminophen",
      "DosageFormName": "TABLET, FILM COATED",
      "RouteName": "ORAL",
      "StartMarketingDate": "20100101",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA074843",
      "LabelerName": "Altura Pharmaceuticals, Inc.",
      "SubstanceName": "PROPOXYPHENE NAPSYLATE; ACETAMINOPHEN",
      "StrengthNumber": "100; 650",
      "StrengthUnit": "mg/1; mg/1",
      "Pharm_Classes": "Full Opioid Agonists [MoA],Opioid Agonist [EPC]",
      "DEASchedule": "CIV",
      "Status": "Deprecated",
      "LastUpdate": "2018-01-10",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "Propoxyphene napsylate and acetaminophen tablets, USP are indicated for the relief of mild to moderate pain.",
      "Description": "Propoxyphene Napsylate, USP is an odorless, white crystalline powder with a bitter taste. It is very slightly soluble in water and soluble in methanol, ethanol, chloroform, and acetone. Chemically, it is (αS,1R)-α-[2-(Dimethylamino)-1-methylethyl]-α-phenylphenethyl propionate compound with 2-napthalenesulfonic acid (1:1) monohydrate, which can be represented by the accompanying structural formula. Propoxyphene napsylate differs from propoxyphene hydrochloride in that it allows more stable liquid dosage forms and tablet formulations. Because of differences in molecular weight, a dose of 100 mg (176.8 μmol) of propoxyphene napsylate is required to supply an amount of propoxyphene equivalent to that present in 65 mg (172.9 μmol) of propoxyphene hydrochloride. Acetaminophen, 4'-hydroxyacetanilide, is a non-opiate, non-salicylate analgesic and antipyretic which occurs as a white, odorless, crystalline powder, possessing a slightly bitter taste. The molecular formula for acetaminophen is C8H9NO2 and the molecular weight is 151.16. It may be represented by the following structural formula. Propoxyphene Napsylate and Acetaminophen Tablets, USP 50 mg/325 mgEach tablet contains:       Propoxyphene Napsylate ............................50 mg (88.4 μmol)       Acetaminophen .........................................325 mg (2150 μmol) In addition each tablet contains the following inactive ingredients: carnauba wax, D&C Yellow #10 Aluminum Lake, FD&C Red #40 Aluminum Lake, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, polysorbate 80, sodium starch glycolate and titanium dioxide. Propoxyphene Napsylate and Acetaminophen Tablets, USP 100 mg/650 mgEach tablet contains:       Propoxyphene Napsylate ...........................100 mg (176.8 μmol)       Acetaminophen ..........................................650 mg (4300 μmol)In addition each tablet contains the following inactive ingredients: carnauba wax, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, polysorbate 80, sodium starch glycolate and titanium dioxide. The orange tablets also contain D&C Yellow #10 Aluminum Lake and FD&C Red #40 Aluminum Lake. The pink tablets also contain FD&C Red #40 Aluminum Lake."
    },
    {
      "NDCCode": "63874-201-60",
      "PackageDescription": "60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (63874-201-60)",
      "NDC11Code": "63874-0201-60",
      "ProductNDC": "63874-201",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Propoxyphene And Acetaminophen",
      "NonProprietaryName": "Propoxyphene Napsylate And Acetaminophen",
      "DosageFormName": "TABLET, FILM COATED",
      "RouteName": "ORAL",
      "StartMarketingDate": "20100101",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA074843",
      "LabelerName": "Altura Pharmaceuticals, Inc.",
      "SubstanceName": "PROPOXYPHENE NAPSYLATE; ACETAMINOPHEN",
      "StrengthNumber": "100; 650",
      "StrengthUnit": "mg/1; mg/1",
      "Pharm_Classes": "Full Opioid Agonists [MoA],Opioid Agonist [EPC]",
      "DEASchedule": "CIV",
      "Status": "Deprecated",
      "LastUpdate": "2018-01-10",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "Propoxyphene napsylate and acetaminophen tablets, USP are indicated for the relief of mild to moderate pain.",
      "Description": "Propoxyphene Napsylate, USP is an odorless, white crystalline powder with a bitter taste. It is very slightly soluble in water and soluble in methanol, ethanol, chloroform, and acetone. Chemically, it is (αS,1R)-α-[2-(Dimethylamino)-1-methylethyl]-α-phenylphenethyl propionate compound with 2-napthalenesulfonic acid (1:1) monohydrate, which can be represented by the accompanying structural formula. Propoxyphene napsylate differs from propoxyphene hydrochloride in that it allows more stable liquid dosage forms and tablet formulations. Because of differences in molecular weight, a dose of 100 mg (176.8 μmol) of propoxyphene napsylate is required to supply an amount of propoxyphene equivalent to that present in 65 mg (172.9 μmol) of propoxyphene hydrochloride. Acetaminophen, 4'-hydroxyacetanilide, is a non-opiate, non-salicylate analgesic and antipyretic which occurs as a white, odorless, crystalline powder, possessing a slightly bitter taste. The molecular formula for acetaminophen is C8H9NO2 and the molecular weight is 151.16. It may be represented by the following structural formula. Propoxyphene Napsylate and Acetaminophen Tablets, USP 50 mg/325 mgEach tablet contains:       Propoxyphene Napsylate ............................50 mg (88.4 μmol)       Acetaminophen .........................................325 mg (2150 μmol) In addition each tablet contains the following inactive ingredients: carnauba wax, D&C Yellow #10 Aluminum Lake, FD&C Red #40 Aluminum Lake, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, polysorbate 80, sodium starch glycolate and titanium dioxide. Propoxyphene Napsylate and Acetaminophen Tablets, USP 100 mg/650 mgEach tablet contains:       Propoxyphene Napsylate ...........................100 mg (176.8 μmol)       Acetaminophen ..........................................650 mg (4300 μmol)In addition each tablet contains the following inactive ingredients: carnauba wax, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, polysorbate 80, sodium starch glycolate and titanium dioxide. The orange tablets also contain D&C Yellow #10 Aluminum Lake and FD&C Red #40 Aluminum Lake. The pink tablets also contain FD&C Red #40 Aluminum Lake."
    },
    {
      "NDCCode": "63874-201-90",
      "PackageDescription": "90 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (63874-201-90)",
      "NDC11Code": "63874-0201-90",
      "ProductNDC": "63874-201",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Propoxyphene And Acetaminophen",
      "NonProprietaryName": "Propoxyphene Napsylate And Acetaminophen",
      "DosageFormName": "TABLET, FILM COATED",
      "RouteName": "ORAL",
      "StartMarketingDate": "20100101",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA074843",
      "LabelerName": "Altura Pharmaceuticals, Inc.",
      "SubstanceName": "PROPOXYPHENE NAPSYLATE; ACETAMINOPHEN",
      "StrengthNumber": "100; 650",
      "StrengthUnit": "mg/1; mg/1",
      "Pharm_Classes": "Full Opioid Agonists [MoA],Opioid Agonist [EPC]",
      "DEASchedule": "CIV",
      "Status": "Deprecated",
      "LastUpdate": "2018-01-10",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "Propoxyphene napsylate and acetaminophen tablets, USP are indicated for the relief of mild to moderate pain.",
      "Description": "Propoxyphene Napsylate, USP is an odorless, white crystalline powder with a bitter taste. It is very slightly soluble in water and soluble in methanol, ethanol, chloroform, and acetone. Chemically, it is (αS,1R)-α-[2-(Dimethylamino)-1-methylethyl]-α-phenylphenethyl propionate compound with 2-napthalenesulfonic acid (1:1) monohydrate, which can be represented by the accompanying structural formula. Propoxyphene napsylate differs from propoxyphene hydrochloride in that it allows more stable liquid dosage forms and tablet formulations. Because of differences in molecular weight, a dose of 100 mg (176.8 μmol) of propoxyphene napsylate is required to supply an amount of propoxyphene equivalent to that present in 65 mg (172.9 μmol) of propoxyphene hydrochloride. Acetaminophen, 4'-hydroxyacetanilide, is a non-opiate, non-salicylate analgesic and antipyretic which occurs as a white, odorless, crystalline powder, possessing a slightly bitter taste. The molecular formula for acetaminophen is C8H9NO2 and the molecular weight is 151.16. It may be represented by the following structural formula. Propoxyphene Napsylate and Acetaminophen Tablets, USP 50 mg/325 mgEach tablet contains:       Propoxyphene Napsylate ............................50 mg (88.4 μmol)       Acetaminophen .........................................325 mg (2150 μmol) In addition each tablet contains the following inactive ingredients: carnauba wax, D&C Yellow #10 Aluminum Lake, FD&C Red #40 Aluminum Lake, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, polysorbate 80, sodium starch glycolate and titanium dioxide. Propoxyphene Napsylate and Acetaminophen Tablets, USP 100 mg/650 mgEach tablet contains:       Propoxyphene Napsylate ...........................100 mg (176.8 μmol)       Acetaminophen ..........................................650 mg (4300 μmol)In addition each tablet contains the following inactive ingredients: carnauba wax, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, polysorbate 80, sodium starch glycolate and titanium dioxide. The orange tablets also contain D&C Yellow #10 Aluminum Lake and FD&C Red #40 Aluminum Lake. The pink tablets also contain FD&C Red #40 Aluminum Lake."
    },
    {
      "NDCCode": "68387-100-10",
      "PackageDescription": "10 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (68387-100-10)",
      "NDC11Code": "68387-0100-10",
      "ProductNDC": "68387-100",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Propoxyphene And Acetaminophen",
      "NonProprietaryName": "Propoxyphene Napsylate And Acetaminophen",
      "DosageFormName": "TABLET, FILM COATED",
      "RouteName": "ORAL",
      "StartMarketingDate": "20090301",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA074843",
      "LabelerName": "Keltman Pharmaceuticals Inc.",
      "SubstanceName": "PROPOXYPHENE NAPSYLATE; ACETAMINOPHEN",
      "StrengthNumber": "100; 650",
      "StrengthUnit": "mg/1; mg/1",
      "Pharm_Classes": "Full Opioid Agonists [MoA],Opioid Agonist [EPC]",
      "DEASchedule": "CIV",
      "Status": "Deprecated",
      "LastUpdate": "2018-01-10",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "Propoxyphene napsylate and acetaminophen tablets, USP are indicated for the relief of mild to moderate pain.",
      "Description": "Propoxyphene Napsylate, USP is an odorless, white crystalline powder with a bitter taste. It is very slightly soluble in water and soluble in methanol, ethanol, chloroform, and acetone. Chemically, it is (αS,1R)-α-[2-(Dimethylamino)-1-methylethyl]-α-phenylphenethyl propionate compound with 2-napthalenesulfonic acid (1:1) monohydrate, which can be represented by the accompanying structural formula. Propoxyphene napsylate differs from propoxyphene hydrochloride in that it allows more stable liquid dosage forms and tablet formulations. Because of differences in molecular weight, a dose of 100 mg (176.8 μmol) of propoxyphene napsylate is required to supply an amount of propoxyphene equivalent to that present in 65 mg (172.9 μmol) of propoxyphene hydrochloride. Acetaminophen, 4'-hydroxyacetanilide, is a non-opiate, non-salicylate analgesic and antipyretic which occurs as a white, odorless, crystalline powder, possessing a slightly bitter taste. The molecular formula for acetaminophen is C8H9NO2 and the molecular weight is 151.16. It may be represented by the following structural formula. Propoxyphene Napsylate and Acetaminophen Tablets, USP 50 mg/325 mgEach tablet contains:       Propoxyphene Napsylate ............................50 mg (88.4 μmol)       Acetaminophen .........................................325 mg (2150 μmol) In addition each tablet contains the following inactive ingredients: carnauba wax, D&C Yellow #10 Aluminum Lake, FD&C Red #40 Aluminum Lake, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, polysorbate 80, sodium starch glycolate and titanium dioxide. Propoxyphene Napsylate and Acetaminophen Tablets, USP 100 mg/650 mgEach tablet contains:       Propoxyphene Napsylate ...........................100 mg (176.8 μmol)       Acetaminophen ..........................................650 mg (4300 μmol)In addition each tablet contains the following inactive ingredients: carnauba wax, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, polysorbate 80, sodium starch glycolate and titanium dioxide. The orange tablets also contain D&C Yellow #10 Aluminum Lake and FD&C Red #40 Aluminum Lake. The pink tablets also contain FD&C Red #40 Aluminum Lake."
    },
    {
      "NDCCode": "68387-100-12",
      "PackageDescription": "120 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (68387-100-12)",
      "NDC11Code": "68387-0100-12",
      "ProductNDC": "68387-100",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Propoxyphene And Acetaminophen",
      "NonProprietaryName": "Propoxyphene Napsylate And Acetaminophen",
      "DosageFormName": "TABLET, FILM COATED",
      "RouteName": "ORAL",
      "StartMarketingDate": "20090301",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA074843",
      "LabelerName": "Keltman Pharmaceuticals Inc.",
      "SubstanceName": "PROPOXYPHENE NAPSYLATE; ACETAMINOPHEN",
      "StrengthNumber": "100; 650",
      "StrengthUnit": "mg/1; mg/1",
      "Pharm_Classes": "Full Opioid Agonists [MoA],Opioid Agonist [EPC]",
      "DEASchedule": "CIV",
      "Status": "Deprecated",
      "LastUpdate": "2018-01-10",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "Propoxyphene napsylate and acetaminophen tablets, USP are indicated for the relief of mild to moderate pain.",
      "Description": "Propoxyphene Napsylate, USP is an odorless, white crystalline powder with a bitter taste. It is very slightly soluble in water and soluble in methanol, ethanol, chloroform, and acetone. Chemically, it is (αS,1R)-α-[2-(Dimethylamino)-1-methylethyl]-α-phenylphenethyl propionate compound with 2-napthalenesulfonic acid (1:1) monohydrate, which can be represented by the accompanying structural formula. Propoxyphene napsylate differs from propoxyphene hydrochloride in that it allows more stable liquid dosage forms and tablet formulations. Because of differences in molecular weight, a dose of 100 mg (176.8 μmol) of propoxyphene napsylate is required to supply an amount of propoxyphene equivalent to that present in 65 mg (172.9 μmol) of propoxyphene hydrochloride. Acetaminophen, 4'-hydroxyacetanilide, is a non-opiate, non-salicylate analgesic and antipyretic which occurs as a white, odorless, crystalline powder, possessing a slightly bitter taste. The molecular formula for acetaminophen is C8H9NO2 and the molecular weight is 151.16. It may be represented by the following structural formula. Propoxyphene Napsylate and Acetaminophen Tablets, USP 50 mg/325 mgEach tablet contains:       Propoxyphene Napsylate ............................50 mg (88.4 μmol)       Acetaminophen .........................................325 mg (2150 μmol) In addition each tablet contains the following inactive ingredients: carnauba wax, D&C Yellow #10 Aluminum Lake, FD&C Red #40 Aluminum Lake, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, polysorbate 80, sodium starch glycolate and titanium dioxide. Propoxyphene Napsylate and Acetaminophen Tablets, USP 100 mg/650 mgEach tablet contains:       Propoxyphene Napsylate ...........................100 mg (176.8 μmol)       Acetaminophen ..........................................650 mg (4300 μmol)In addition each tablet contains the following inactive ingredients: carnauba wax, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, polysorbate 80, sodium starch glycolate and titanium dioxide. The orange tablets also contain D&C Yellow #10 Aluminum Lake and FD&C Red #40 Aluminum Lake. The pink tablets also contain FD&C Red #40 Aluminum Lake."
    },
    {
      "NDCCode": "68387-100-15",
      "PackageDescription": "15 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (68387-100-15)",
      "NDC11Code": "68387-0100-15",
      "ProductNDC": "68387-100",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Propoxyphene And Acetaminophen",
      "NonProprietaryName": "Propoxyphene Napsylate And Acetaminophen",
      "DosageFormName": "TABLET, FILM COATED",
      "RouteName": "ORAL",
      "StartMarketingDate": "20090301",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA074843",
      "LabelerName": "Keltman Pharmaceuticals Inc.",
      "SubstanceName": "PROPOXYPHENE NAPSYLATE; ACETAMINOPHEN",
      "StrengthNumber": "100; 650",
      "StrengthUnit": "mg/1; mg/1",
      "Pharm_Classes": "Full Opioid Agonists [MoA],Opioid Agonist [EPC]",
      "DEASchedule": "CIV",
      "Status": "Deprecated",
      "LastUpdate": "2018-01-10",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "Propoxyphene napsylate and acetaminophen tablets, USP are indicated for the relief of mild to moderate pain.",
      "Description": "Propoxyphene Napsylate, USP is an odorless, white crystalline powder with a bitter taste. It is very slightly soluble in water and soluble in methanol, ethanol, chloroform, and acetone. Chemically, it is (αS,1R)-α-[2-(Dimethylamino)-1-methylethyl]-α-phenylphenethyl propionate compound with 2-napthalenesulfonic acid (1:1) monohydrate, which can be represented by the accompanying structural formula. Propoxyphene napsylate differs from propoxyphene hydrochloride in that it allows more stable liquid dosage forms and tablet formulations. Because of differences in molecular weight, a dose of 100 mg (176.8 μmol) of propoxyphene napsylate is required to supply an amount of propoxyphene equivalent to that present in 65 mg (172.9 μmol) of propoxyphene hydrochloride. Acetaminophen, 4'-hydroxyacetanilide, is a non-opiate, non-salicylate analgesic and antipyretic which occurs as a white, odorless, crystalline powder, possessing a slightly bitter taste. The molecular formula for acetaminophen is C8H9NO2 and the molecular weight is 151.16. It may be represented by the following structural formula. Propoxyphene Napsylate and Acetaminophen Tablets, USP 50 mg/325 mgEach tablet contains:       Propoxyphene Napsylate ............................50 mg (88.4 μmol)       Acetaminophen .........................................325 mg (2150 μmol) In addition each tablet contains the following inactive ingredients: carnauba wax, D&C Yellow #10 Aluminum Lake, FD&C Red #40 Aluminum Lake, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, polysorbate 80, sodium starch glycolate and titanium dioxide. Propoxyphene Napsylate and Acetaminophen Tablets, USP 100 mg/650 mgEach tablet contains:       Propoxyphene Napsylate ...........................100 mg (176.8 μmol)       Acetaminophen ..........................................650 mg (4300 μmol)In addition each tablet contains the following inactive ingredients: carnauba wax, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, polysorbate 80, sodium starch glycolate and titanium dioxide. The orange tablets also contain D&C Yellow #10 Aluminum Lake and FD&C Red #40 Aluminum Lake. The pink tablets also contain FD&C Red #40 Aluminum Lake."
    },
    {
      "NDCCode": "68387-100-30",
      "PackageDescription": "30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (68387-100-30)",
      "NDC11Code": "68387-0100-30",
      "ProductNDC": "68387-100",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Propoxyphene And Acetaminophen",
      "NonProprietaryName": "Propoxyphene Napsylate And Acetaminophen",
      "DosageFormName": "TABLET, FILM COATED",
      "RouteName": "ORAL",
      "StartMarketingDate": "20090301",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA074843",
      "LabelerName": "Keltman Pharmaceuticals Inc.",
      "SubstanceName": "PROPOXYPHENE NAPSYLATE; ACETAMINOPHEN",
      "StrengthNumber": "100; 650",
      "StrengthUnit": "mg/1; mg/1",
      "Pharm_Classes": "Full Opioid Agonists [MoA],Opioid Agonist [EPC]",
      "DEASchedule": "CIV",
      "Status": "Deprecated",
      "LastUpdate": "2018-01-10",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "Propoxyphene napsylate and acetaminophen tablets, USP are indicated for the relief of mild to moderate pain.",
      "Description": "Propoxyphene Napsylate, USP is an odorless, white crystalline powder with a bitter taste. It is very slightly soluble in water and soluble in methanol, ethanol, chloroform, and acetone. Chemically, it is (αS,1R)-α-[2-(Dimethylamino)-1-methylethyl]-α-phenylphenethyl propionate compound with 2-napthalenesulfonic acid (1:1) monohydrate, which can be represented by the accompanying structural formula. Propoxyphene napsylate differs from propoxyphene hydrochloride in that it allows more stable liquid dosage forms and tablet formulations. Because of differences in molecular weight, a dose of 100 mg (176.8 μmol) of propoxyphene napsylate is required to supply an amount of propoxyphene equivalent to that present in 65 mg (172.9 μmol) of propoxyphene hydrochloride. Acetaminophen, 4'-hydroxyacetanilide, is a non-opiate, non-salicylate analgesic and antipyretic which occurs as a white, odorless, crystalline powder, possessing a slightly bitter taste. The molecular formula for acetaminophen is C8H9NO2 and the molecular weight is 151.16. It may be represented by the following structural formula. Propoxyphene Napsylate and Acetaminophen Tablets, USP 50 mg/325 mgEach tablet contains:       Propoxyphene Napsylate ............................50 mg (88.4 μmol)       Acetaminophen .........................................325 mg (2150 μmol) In addition each tablet contains the following inactive ingredients: carnauba wax, D&C Yellow #10 Aluminum Lake, FD&C Red #40 Aluminum Lake, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, polysorbate 80, sodium starch glycolate and titanium dioxide. Propoxyphene Napsylate and Acetaminophen Tablets, USP 100 mg/650 mgEach tablet contains:       Propoxyphene Napsylate ...........................100 mg (176.8 μmol)       Acetaminophen ..........................................650 mg (4300 μmol)In addition each tablet contains the following inactive ingredients: carnauba wax, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, polysorbate 80, sodium starch glycolate and titanium dioxide. The orange tablets also contain D&C Yellow #10 Aluminum Lake and FD&C Red #40 Aluminum Lake. The pink tablets also contain FD&C Red #40 Aluminum Lake."
    },
    {
      "NDCCode": "68387-100-40",
      "PackageDescription": "40 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (68387-100-40)",
      "NDC11Code": "68387-0100-40",
      "ProductNDC": "68387-100",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Propoxyphene And Acetaminophen",
      "NonProprietaryName": "Propoxyphene Napsylate And Acetaminophen",
      "DosageFormName": "TABLET, FILM COATED",
      "RouteName": "ORAL",
      "StartMarketingDate": "20090301",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA074843",
      "LabelerName": "Keltman Pharmaceuticals Inc.",
      "SubstanceName": "PROPOXYPHENE NAPSYLATE; ACETAMINOPHEN",
      "StrengthNumber": "100; 650",
      "StrengthUnit": "mg/1; mg/1",
      "Pharm_Classes": "Full Opioid Agonists [MoA],Opioid Agonist [EPC]",
      "DEASchedule": "CIV",
      "Status": "Deprecated",
      "LastUpdate": "2018-01-10",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "Propoxyphene napsylate and acetaminophen tablets, USP are indicated for the relief of mild to moderate pain.",
      "Description": "Propoxyphene Napsylate, USP is an odorless, white crystalline powder with a bitter taste. It is very slightly soluble in water and soluble in methanol, ethanol, chloroform, and acetone. Chemically, it is (αS,1R)-α-[2-(Dimethylamino)-1-methylethyl]-α-phenylphenethyl propionate compound with 2-napthalenesulfonic acid (1:1) monohydrate, which can be represented by the accompanying structural formula. Propoxyphene napsylate differs from propoxyphene hydrochloride in that it allows more stable liquid dosage forms and tablet formulations. Because of differences in molecular weight, a dose of 100 mg (176.8 μmol) of propoxyphene napsylate is required to supply an amount of propoxyphene equivalent to that present in 65 mg (172.9 μmol) of propoxyphene hydrochloride. Acetaminophen, 4'-hydroxyacetanilide, is a non-opiate, non-salicylate analgesic and antipyretic which occurs as a white, odorless, crystalline powder, possessing a slightly bitter taste. The molecular formula for acetaminophen is C8H9NO2 and the molecular weight is 151.16. It may be represented by the following structural formula. Propoxyphene Napsylate and Acetaminophen Tablets, USP 50 mg/325 mgEach tablet contains:       Propoxyphene Napsylate ............................50 mg (88.4 μmol)       Acetaminophen .........................................325 mg (2150 μmol) In addition each tablet contains the following inactive ingredients: carnauba wax, D&C Yellow #10 Aluminum Lake, FD&C Red #40 Aluminum Lake, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, polysorbate 80, sodium starch glycolate and titanium dioxide. Propoxyphene Napsylate and Acetaminophen Tablets, USP 100 mg/650 mgEach tablet contains:       Propoxyphene Napsylate ...........................100 mg (176.8 μmol)       Acetaminophen ..........................................650 mg (4300 μmol)In addition each tablet contains the following inactive ingredients: carnauba wax, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, polysorbate 80, sodium starch glycolate and titanium dioxide. The orange tablets also contain D&C Yellow #10 Aluminum Lake and FD&C Red #40 Aluminum Lake. The pink tablets also contain FD&C Red #40 Aluminum Lake."
    },
    {
      "NDCCode": "68387-100-50",
      "PackageDescription": "50 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (68387-100-50)",
      "NDC11Code": "68387-0100-50",
      "ProductNDC": "68387-100",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Propoxyphene And Acetaminophen",
      "NonProprietaryName": "Propoxyphene Napsylate And Acetaminophen",
      "DosageFormName": "TABLET, FILM COATED",
      "RouteName": "ORAL",
      "StartMarketingDate": "20090301",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA074843",
      "LabelerName": "Keltman Pharmaceuticals Inc.",
      "SubstanceName": "PROPOXYPHENE NAPSYLATE; ACETAMINOPHEN",
      "StrengthNumber": "100; 650",
      "StrengthUnit": "mg/1; mg/1",
      "Pharm_Classes": "Full Opioid Agonists [MoA],Opioid Agonist [EPC]",
      "DEASchedule": "CIV",
      "Status": "Deprecated",
      "LastUpdate": "2018-01-10",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "Propoxyphene napsylate and acetaminophen tablets, USP are indicated for the relief of mild to moderate pain.",
      "Description": "Propoxyphene Napsylate, USP is an odorless, white crystalline powder with a bitter taste. It is very slightly soluble in water and soluble in methanol, ethanol, chloroform, and acetone. Chemically, it is (αS,1R)-α-[2-(Dimethylamino)-1-methylethyl]-α-phenylphenethyl propionate compound with 2-napthalenesulfonic acid (1:1) monohydrate, which can be represented by the accompanying structural formula. Propoxyphene napsylate differs from propoxyphene hydrochloride in that it allows more stable liquid dosage forms and tablet formulations. Because of differences in molecular weight, a dose of 100 mg (176.8 μmol) of propoxyphene napsylate is required to supply an amount of propoxyphene equivalent to that present in 65 mg (172.9 μmol) of propoxyphene hydrochloride. Acetaminophen, 4'-hydroxyacetanilide, is a non-opiate, non-salicylate analgesic and antipyretic which occurs as a white, odorless, crystalline powder, possessing a slightly bitter taste. The molecular formula for acetaminophen is C8H9NO2 and the molecular weight is 151.16. It may be represented by the following structural formula. Propoxyphene Napsylate and Acetaminophen Tablets, USP 50 mg/325 mgEach tablet contains:       Propoxyphene Napsylate ............................50 mg (88.4 μmol)       Acetaminophen .........................................325 mg (2150 μmol) In addition each tablet contains the following inactive ingredients: carnauba wax, D&C Yellow #10 Aluminum Lake, FD&C Red #40 Aluminum Lake, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, polysorbate 80, sodium starch glycolate and titanium dioxide. Propoxyphene Napsylate and Acetaminophen Tablets, USP 100 mg/650 mgEach tablet contains:       Propoxyphene Napsylate ...........................100 mg (176.8 μmol)       Acetaminophen ..........................................650 mg (4300 μmol)In addition each tablet contains the following inactive ingredients: carnauba wax, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, polysorbate 80, sodium starch glycolate and titanium dioxide. The orange tablets also contain D&C Yellow #10 Aluminum Lake and FD&C Red #40 Aluminum Lake. The pink tablets also contain FD&C Red #40 Aluminum Lake."
    },
    {
      "NDCCode": "68387-100-60",
      "PackageDescription": "60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (68387-100-60)",
      "NDC11Code": "68387-0100-60",
      "ProductNDC": "68387-100",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Propoxyphene And Acetaminophen",
      "NonProprietaryName": "Propoxyphene Napsylate And Acetaminophen",
      "DosageFormName": "TABLET, FILM COATED",
      "RouteName": "ORAL",
      "StartMarketingDate": "20090301",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA074843",
      "LabelerName": "Keltman Pharmaceuticals Inc.",
      "SubstanceName": "PROPOXYPHENE NAPSYLATE; ACETAMINOPHEN",
      "StrengthNumber": "100; 650",
      "StrengthUnit": "mg/1; mg/1",
      "Pharm_Classes": "Full Opioid Agonists [MoA],Opioid Agonist [EPC]",
      "DEASchedule": "CIV",
      "Status": "Deprecated",
      "LastUpdate": "2018-01-10",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "Propoxyphene napsylate and acetaminophen tablets, USP are indicated for the relief of mild to moderate pain.",
      "Description": "Propoxyphene Napsylate, USP is an odorless, white crystalline powder with a bitter taste. It is very slightly soluble in water and soluble in methanol, ethanol, chloroform, and acetone. Chemically, it is (αS,1R)-α-[2-(Dimethylamino)-1-methylethyl]-α-phenylphenethyl propionate compound with 2-napthalenesulfonic acid (1:1) monohydrate, which can be represented by the accompanying structural formula. Propoxyphene napsylate differs from propoxyphene hydrochloride in that it allows more stable liquid dosage forms and tablet formulations. Because of differences in molecular weight, a dose of 100 mg (176.8 μmol) of propoxyphene napsylate is required to supply an amount of propoxyphene equivalent to that present in 65 mg (172.9 μmol) of propoxyphene hydrochloride. Acetaminophen, 4'-hydroxyacetanilide, is a non-opiate, non-salicylate analgesic and antipyretic which occurs as a white, odorless, crystalline powder, possessing a slightly bitter taste. The molecular formula for acetaminophen is C8H9NO2 and the molecular weight is 151.16. It may be represented by the following structural formula. Propoxyphene Napsylate and Acetaminophen Tablets, USP 50 mg/325 mgEach tablet contains:       Propoxyphene Napsylate ............................50 mg (88.4 μmol)       Acetaminophen .........................................325 mg (2150 μmol) In addition each tablet contains the following inactive ingredients: carnauba wax, D&C Yellow #10 Aluminum Lake, FD&C Red #40 Aluminum Lake, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, polysorbate 80, sodium starch glycolate and titanium dioxide. Propoxyphene Napsylate and Acetaminophen Tablets, USP 100 mg/650 mgEach tablet contains:       Propoxyphene Napsylate ...........................100 mg (176.8 μmol)       Acetaminophen ..........................................650 mg (4300 μmol)In addition each tablet contains the following inactive ingredients: carnauba wax, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, polysorbate 80, sodium starch glycolate and titanium dioxide. The orange tablets also contain D&C Yellow #10 Aluminum Lake and FD&C Red #40 Aluminum Lake. The pink tablets also contain FD&C Red #40 Aluminum Lake."
    },
    {
      "NDCCode": "68387-100-90",
      "PackageDescription": "90 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (68387-100-90)",
      "NDC11Code": "68387-0100-90",
      "ProductNDC": "68387-100",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Propoxyphene And Acetaminophen",
      "NonProprietaryName": "Propoxyphene Napsylate And Acetaminophen",
      "DosageFormName": "TABLET, FILM COATED",
      "RouteName": "ORAL",
      "StartMarketingDate": "20090301",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA074843",
      "LabelerName": "Keltman Pharmaceuticals Inc.",
      "SubstanceName": "PROPOXYPHENE NAPSYLATE; ACETAMINOPHEN",
      "StrengthNumber": "100; 650",
      "StrengthUnit": "mg/1; mg/1",
      "Pharm_Classes": "Full Opioid Agonists [MoA],Opioid Agonist [EPC]",
      "DEASchedule": "CIV",
      "Status": "Deprecated",
      "LastUpdate": "2018-01-10",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "Propoxyphene napsylate and acetaminophen tablets, USP are indicated for the relief of mild to moderate pain.",
      "Description": "Propoxyphene Napsylate, USP is an odorless, white crystalline powder with a bitter taste. It is very slightly soluble in water and soluble in methanol, ethanol, chloroform, and acetone. Chemically, it is (αS,1R)-α-[2-(Dimethylamino)-1-methylethyl]-α-phenylphenethyl propionate compound with 2-napthalenesulfonic acid (1:1) monohydrate, which can be represented by the accompanying structural formula. Propoxyphene napsylate differs from propoxyphene hydrochloride in that it allows more stable liquid dosage forms and tablet formulations. Because of differences in molecular weight, a dose of 100 mg (176.8 μmol) of propoxyphene napsylate is required to supply an amount of propoxyphene equivalent to that present in 65 mg (172.9 μmol) of propoxyphene hydrochloride. Acetaminophen, 4'-hydroxyacetanilide, is a non-opiate, non-salicylate analgesic and antipyretic which occurs as a white, odorless, crystalline powder, possessing a slightly bitter taste. The molecular formula for acetaminophen is C8H9NO2 and the molecular weight is 151.16. It may be represented by the following structural formula. Propoxyphene Napsylate and Acetaminophen Tablets, USP 50 mg/325 mgEach tablet contains:       Propoxyphene Napsylate ............................50 mg (88.4 μmol)       Acetaminophen .........................................325 mg (2150 μmol) In addition each tablet contains the following inactive ingredients: carnauba wax, D&C Yellow #10 Aluminum Lake, FD&C Red #40 Aluminum Lake, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, polysorbate 80, sodium starch glycolate and titanium dioxide. Propoxyphene Napsylate and Acetaminophen Tablets, USP 100 mg/650 mgEach tablet contains:       Propoxyphene Napsylate ...........................100 mg (176.8 μmol)       Acetaminophen ..........................................650 mg (4300 μmol)In addition each tablet contains the following inactive ingredients: carnauba wax, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, polysorbate 80, sodium starch glycolate and titanium dioxide. The orange tablets also contain D&C Yellow #10 Aluminum Lake and FD&C Red #40 Aluminum Lake. The pink tablets also contain FD&C Red #40 Aluminum Lake."
    },
    {
      "NDCCode": "71335-2150-1",
      "PackageDescription": "30 TABLET in 1 BOTTLE, PLASTIC (71335-2150-1) ",
      "NDC11Code": "71335-2150-01",
      "ProductNDC": "71335-2150",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Buspirone Hydrochloride",
      "NonProprietaryName": "Buspirone Hydrochloride",
      "DosageFormName": "TABLET",
      "RouteName": "ORAL",
      "StartMarketingDate": "20130708",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA076008",
      "LabelerName": "Bryant Ranch Prepack",
      "SubstanceName": "BUSPIRONE HYDROCHLORIDE",
      "StrengthNumber": "7.5",
      "StrengthUnit": "mg/1",
      "Status": "Deprecated",
      "LastUpdate": "2026-04-30",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20261231",
      "StartMarketingDatePackage": "20220822",
      "SamplePackage": "N",
      "IndicationAndUsage": "Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association’s Diagnostic and Statistical Manual, III1 as follows. Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: 1 1.Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle., 2 2.Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate., 3 3.Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others., 4 4.Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling “on edge,” irritability, impatience.",
      "Description": "Buspirone hydrochloride tablets, USP are an antianxiety agent that are not chemically or pharmacologically related to the benzodiazepines, barbiturates, or other sedative/anxiolytic drugs. Buspirone hydrochloride, USP is a white crystalline, water soluble compound with a molecular weight of 422.0. Chemically, buspirone hydrochloride is 8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione monohydrochloride. The molecular formula C21H31N5O2HCl is represented by the following structural formula. Buspirone hydrochloride tablets are supplied as tablets for oral administration containing 5 mg, 7.5 mg, 10 mg, 15 mg or 30 mg of buspirone hydrochloride, USP (equivalent to 4.6 mg, 6.9 mg, 9.1 mg, 13.7 mg, and 27.4 mg of buspirone free base, respectively). The 5 mg and 10 mg tablets are scored so they can be bisected. Thus, the 5 mg tablet can also provide a 2.5 mg dose, and the 10 mg tablet can provide a 5 mg dose. The 15 mg and 30 mg tablets are provided in a multi-scored tablet design. These tablets are scored so they can be either bisected or trisected. Thus, a single 15 mg tablet can provide the following doses: 15 mg (entire tablet), 10 mg (two thirds of a tablet), 7.5 mg (one half of a tablet), or 5 mg (one third of a tablet). A single 30 mg tablet can provide the following doses: 30 mg (entire tablet), 20 mg (two thirds of a tablet), 15 mg (one half of a tablet), or 10 mg (one third of a tablet). Buspirone hydrochloride tablets contain the following inactive ingredients: anhydrous lactose, colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate, and sodium starch glycolate (potato)."
    },
    {
      "NDCCode": "71335-2150-2",
      "PackageDescription": "90 TABLET in 1 BOTTLE, PLASTIC (71335-2150-2) ",
      "NDC11Code": "71335-2150-02",
      "ProductNDC": "71335-2150",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Buspirone Hydrochloride",
      "NonProprietaryName": "Buspirone Hydrochloride",
      "DosageFormName": "TABLET",
      "RouteName": "ORAL",
      "StartMarketingDate": "20130708",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA076008",
      "LabelerName": "Bryant Ranch Prepack",
      "SubstanceName": "BUSPIRONE HYDROCHLORIDE",
      "StrengthNumber": "7.5",
      "StrengthUnit": "mg/1",
      "Status": "Deprecated",
      "LastUpdate": "2026-04-30",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20261231",
      "StartMarketingDatePackage": "20220822",
      "SamplePackage": "N",
      "IndicationAndUsage": "Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association’s Diagnostic and Statistical Manual, III1 as follows. Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: 1 1.Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle., 2 2.Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate., 3 3.Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others., 4 4.Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling “on edge,” irritability, impatience.",
      "Description": "Buspirone hydrochloride tablets, USP are an antianxiety agent that are not chemically or pharmacologically related to the benzodiazepines, barbiturates, or other sedative/anxiolytic drugs. Buspirone hydrochloride, USP is a white crystalline, water soluble compound with a molecular weight of 422.0. Chemically, buspirone hydrochloride is 8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione monohydrochloride. The molecular formula C21H31N5O2HCl is represented by the following structural formula. Buspirone hydrochloride tablets are supplied as tablets for oral administration containing 5 mg, 7.5 mg, 10 mg, 15 mg or 30 mg of buspirone hydrochloride, USP (equivalent to 4.6 mg, 6.9 mg, 9.1 mg, 13.7 mg, and 27.4 mg of buspirone free base, respectively). The 5 mg and 10 mg tablets are scored so they can be bisected. Thus, the 5 mg tablet can also provide a 2.5 mg dose, and the 10 mg tablet can provide a 5 mg dose. The 15 mg and 30 mg tablets are provided in a multi-scored tablet design. These tablets are scored so they can be either bisected or trisected. Thus, a single 15 mg tablet can provide the following doses: 15 mg (entire tablet), 10 mg (two thirds of a tablet), 7.5 mg (one half of a tablet), or 5 mg (one third of a tablet). A single 30 mg tablet can provide the following doses: 30 mg (entire tablet), 20 mg (two thirds of a tablet), 15 mg (one half of a tablet), or 10 mg (one third of a tablet). Buspirone hydrochloride tablets contain the following inactive ingredients: anhydrous lactose, colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate, and sodium starch glycolate (potato)."
    },
    {
      "NDCCode": "71335-2150-3",
      "PackageDescription": "18 TABLET in 1 BOTTLE, PLASTIC (71335-2150-3) ",
      "NDC11Code": "71335-2150-03",
      "ProductNDC": "71335-2150",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Buspirone Hydrochloride",
      "NonProprietaryName": "Buspirone Hydrochloride",
      "DosageFormName": "TABLET",
      "RouteName": "ORAL",
      "StartMarketingDate": "20130708",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA076008",
      "LabelerName": "Bryant Ranch Prepack",
      "SubstanceName": "BUSPIRONE HYDROCHLORIDE",
      "StrengthNumber": "7.5",
      "StrengthUnit": "mg/1",
      "Status": "Deprecated",
      "LastUpdate": "2026-04-30",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20261231",
      "StartMarketingDatePackage": "20220822",
      "SamplePackage": "N",
      "IndicationAndUsage": "Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association’s Diagnostic and Statistical Manual, III1 as follows. Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: 1 1.Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle., 2 2.Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate., 3 3.Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others., 4 4.Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling “on edge,” irritability, impatience.",
      "Description": "Buspirone hydrochloride tablets, USP are an antianxiety agent that are not chemically or pharmacologically related to the benzodiazepines, barbiturates, or other sedative/anxiolytic drugs. Buspirone hydrochloride, USP is a white crystalline, water soluble compound with a molecular weight of 422.0. Chemically, buspirone hydrochloride is 8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione monohydrochloride. The molecular formula C21H31N5O2HCl is represented by the following structural formula. Buspirone hydrochloride tablets are supplied as tablets for oral administration containing 5 mg, 7.5 mg, 10 mg, 15 mg or 30 mg of buspirone hydrochloride, USP (equivalent to 4.6 mg, 6.9 mg, 9.1 mg, 13.7 mg, and 27.4 mg of buspirone free base, respectively). The 5 mg and 10 mg tablets are scored so they can be bisected. Thus, the 5 mg tablet can also provide a 2.5 mg dose, and the 10 mg tablet can provide a 5 mg dose. The 15 mg and 30 mg tablets are provided in a multi-scored tablet design. These tablets are scored so they can be either bisected or trisected. Thus, a single 15 mg tablet can provide the following doses: 15 mg (entire tablet), 10 mg (two thirds of a tablet), 7.5 mg (one half of a tablet), or 5 mg (one third of a tablet). A single 30 mg tablet can provide the following doses: 30 mg (entire tablet), 20 mg (two thirds of a tablet), 15 mg (one half of a tablet), or 10 mg (one third of a tablet). Buspirone hydrochloride tablets contain the following inactive ingredients: anhydrous lactose, colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate, and sodium starch glycolate (potato)."
    },
    {
      "NDCCode": "71335-2150-4",
      "PackageDescription": "28 TABLET in 1 BOTTLE, PLASTIC (71335-2150-4) ",
      "NDC11Code": "71335-2150-04",
      "ProductNDC": "71335-2150",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Buspirone Hydrochloride",
      "NonProprietaryName": "Buspirone Hydrochloride",
      "DosageFormName": "TABLET",
      "RouteName": "ORAL",
      "StartMarketingDate": "20130708",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA076008",
      "LabelerName": "Bryant Ranch Prepack",
      "SubstanceName": "BUSPIRONE HYDROCHLORIDE",
      "StrengthNumber": "7.5",
      "StrengthUnit": "mg/1",
      "Status": "Deprecated",
      "LastUpdate": "2026-04-30",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20261231",
      "StartMarketingDatePackage": "20220822",
      "SamplePackage": "N",
      "IndicationAndUsage": "Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association’s Diagnostic and Statistical Manual, III1 as follows. Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: 1 1.Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle., 2 2.Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate., 3 3.Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others., 4 4.Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling “on edge,” irritability, impatience.",
      "Description": "Buspirone hydrochloride tablets, USP are an antianxiety agent that are not chemically or pharmacologically related to the benzodiazepines, barbiturates, or other sedative/anxiolytic drugs. Buspirone hydrochloride, USP is a white crystalline, water soluble compound with a molecular weight of 422.0. Chemically, buspirone hydrochloride is 8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione monohydrochloride. The molecular formula C21H31N5O2HCl is represented by the following structural formula. Buspirone hydrochloride tablets are supplied as tablets for oral administration containing 5 mg, 7.5 mg, 10 mg, 15 mg or 30 mg of buspirone hydrochloride, USP (equivalent to 4.6 mg, 6.9 mg, 9.1 mg, 13.7 mg, and 27.4 mg of buspirone free base, respectively). The 5 mg and 10 mg tablets are scored so they can be bisected. Thus, the 5 mg tablet can also provide a 2.5 mg dose, and the 10 mg tablet can provide a 5 mg dose. The 15 mg and 30 mg tablets are provided in a multi-scored tablet design. These tablets are scored so they can be either bisected or trisected. Thus, a single 15 mg tablet can provide the following doses: 15 mg (entire tablet), 10 mg (two thirds of a tablet), 7.5 mg (one half of a tablet), or 5 mg (one third of a tablet). A single 30 mg tablet can provide the following doses: 30 mg (entire tablet), 20 mg (two thirds of a tablet), 15 mg (one half of a tablet), or 10 mg (one third of a tablet). Buspirone hydrochloride tablets contain the following inactive ingredients: anhydrous lactose, colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate, and sodium starch glycolate (potato)."
    },
    {
      "NDCCode": "71335-2150-5",
      "PackageDescription": "60 TABLET in 1 BOTTLE, PLASTIC (71335-2150-5) ",
      "NDC11Code": "71335-2150-05",
      "ProductNDC": "71335-2150",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Buspirone Hydrochloride",
      "NonProprietaryName": "Buspirone Hydrochloride",
      "DosageFormName": "TABLET",
      "RouteName": "ORAL",
      "StartMarketingDate": "20130708",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA076008",
      "LabelerName": "Bryant Ranch Prepack",
      "SubstanceName": "BUSPIRONE HYDROCHLORIDE",
      "StrengthNumber": "7.5",
      "StrengthUnit": "mg/1",
      "Status": "Deprecated",
      "LastUpdate": "2026-04-30",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20261231",
      "StartMarketingDatePackage": "20220822",
      "SamplePackage": "N",
      "IndicationAndUsage": "Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association’s Diagnostic and Statistical Manual, III1 as follows. Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: 1 1.Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle., 2 2.Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate., 3 3.Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others., 4 4.Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling “on edge,” irritability, impatience.",
      "Description": "Buspirone hydrochloride tablets, USP are an antianxiety agent that are not chemically or pharmacologically related to the benzodiazepines, barbiturates, or other sedative/anxiolytic drugs. Buspirone hydrochloride, USP is a white crystalline, water soluble compound with a molecular weight of 422.0. Chemically, buspirone hydrochloride is 8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione monohydrochloride. The molecular formula C21H31N5O2HCl is represented by the following structural formula. Buspirone hydrochloride tablets are supplied as tablets for oral administration containing 5 mg, 7.5 mg, 10 mg, 15 mg or 30 mg of buspirone hydrochloride, USP (equivalent to 4.6 mg, 6.9 mg, 9.1 mg, 13.7 mg, and 27.4 mg of buspirone free base, respectively). The 5 mg and 10 mg tablets are scored so they can be bisected. Thus, the 5 mg tablet can also provide a 2.5 mg dose, and the 10 mg tablet can provide a 5 mg dose. The 15 mg and 30 mg tablets are provided in a multi-scored tablet design. These tablets are scored so they can be either bisected or trisected. Thus, a single 15 mg tablet can provide the following doses: 15 mg (entire tablet), 10 mg (two thirds of a tablet), 7.5 mg (one half of a tablet), or 5 mg (one third of a tablet). A single 30 mg tablet can provide the following doses: 30 mg (entire tablet), 20 mg (two thirds of a tablet), 15 mg (one half of a tablet), or 10 mg (one third of a tablet). Buspirone hydrochloride tablets contain the following inactive ingredients: anhydrous lactose, colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate, and sodium starch glycolate (potato)."
    },
    {
      "NDCCode": "71335-2150-6",
      "PackageDescription": "120 TABLET in 1 BOTTLE, PLASTIC (71335-2150-6) ",
      "NDC11Code": "71335-2150-06",
      "ProductNDC": "71335-2150",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Buspirone Hydrochloride",
      "NonProprietaryName": "Buspirone Hydrochloride",
      "DosageFormName": "TABLET",
      "RouteName": "ORAL",
      "StartMarketingDate": "20130708",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA076008",
      "LabelerName": "Bryant Ranch Prepack",
      "SubstanceName": "BUSPIRONE HYDROCHLORIDE",
      "StrengthNumber": "7.5",
      "StrengthUnit": "mg/1",
      "Status": "Deprecated",
      "LastUpdate": "2026-04-30",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20261231",
      "StartMarketingDatePackage": "20220822",
      "SamplePackage": "N",
      "IndicationAndUsage": "Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association’s Diagnostic and Statistical Manual, III1 as follows. Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: 1 1.Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle., 2 2.Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate., 3 3.Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others., 4 4.Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling “on edge,” irritability, impatience.",
      "Description": "Buspirone hydrochloride tablets, USP are an antianxiety agent that are not chemically or pharmacologically related to the benzodiazepines, barbiturates, or other sedative/anxiolytic drugs. Buspirone hydrochloride, USP is a white crystalline, water soluble compound with a molecular weight of 422.0. Chemically, buspirone hydrochloride is 8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione monohydrochloride. The molecular formula C21H31N5O2HCl is represented by the following structural formula. Buspirone hydrochloride tablets are supplied as tablets for oral administration containing 5 mg, 7.5 mg, 10 mg, 15 mg or 30 mg of buspirone hydrochloride, USP (equivalent to 4.6 mg, 6.9 mg, 9.1 mg, 13.7 mg, and 27.4 mg of buspirone free base, respectively). The 5 mg and 10 mg tablets are scored so they can be bisected. Thus, the 5 mg tablet can also provide a 2.5 mg dose, and the 10 mg tablet can provide a 5 mg dose. The 15 mg and 30 mg tablets are provided in a multi-scored tablet design. These tablets are scored so they can be either bisected or trisected. Thus, a single 15 mg tablet can provide the following doses: 15 mg (entire tablet), 10 mg (two thirds of a tablet), 7.5 mg (one half of a tablet), or 5 mg (one third of a tablet). A single 30 mg tablet can provide the following doses: 30 mg (entire tablet), 20 mg (two thirds of a tablet), 15 mg (one half of a tablet), or 10 mg (one third of a tablet). Buspirone hydrochloride tablets contain the following inactive ingredients: anhydrous lactose, colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate, and sodium starch glycolate (potato)."
    },
    {
      "NDCCode": "75857-0001-0",
      "PackageDescription": "10 POUCH in 1 PACKAGE (75857-0001-0)  > 2.5 g in 1 POUCH",
      "NDC11Code": "75857-0001-00",
      "ProductNDC": "75857-0001",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Antibacterial Wet Wipes",
      "NonProprietaryName": "Benzalkonium Chloride",
      "DosageFormName": "LIQUID",
      "RouteName": "TOPICAL",
      "StartMarketingDate": "20130814",
      "MarketingCategoryName": "OTC MONOGRAPH NOT FINAL",
      "ApplicationNumber": "part333E",
      "LabelerName": "Ningbo Dowland Daily Health Co., Ltd",
      "SubstanceName": "BENZALKONIUM CHLORIDE",
      "StrengthNumber": ".13",
      "StrengthUnit": "g/100g",
      "Status": "Deprecated",
      "LastUpdate": "2017-02-07"
    },
    {
      "NDCCode": "75857-0003-0",
      "PackageDescription": "30 POUCH in 1 PACKAGE (75857-0003-0)  > 2.5 g in 1 POUCH",
      "NDC11Code": "75857-0003-00",
      "ProductNDC": "75857-0003",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Antibacterial Wet Wipes",
      "NonProprietaryName": "Benzalkonium Chloride",
      "DosageFormName": "LIQUID",
      "RouteName": "TOPICAL",
      "StartMarketingDate": "20130828",
      "MarketingCategoryName": "OTC MONOGRAPH NOT FINAL",
      "ApplicationNumber": "part333E",
      "LabelerName": "Ningbo Dowland Daily Health Co., Ltd",
      "SubstanceName": "BENZALKONIUM CHLORIDE",
      "StrengthNumber": ".13",
      "StrengthUnit": "g/100g",
      "Status": "Deprecated",
      "LastUpdate": "2017-02-07"
    },
    {
      "NDCCode": "75857-1000-2",
      "PackageDescription": "56.7 g in 1 BOTTLE (75857-1000-2)",
      "NDC11Code": "75857-1000-02",
      "ProductNDC": "75857-1000",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Antibacterial Hand Sanitizer - Citrus Scent",
      "NonProprietaryName": "Ethyl Alcohol",
      "DosageFormName": "GEL",
      "RouteName": "TOPICAL",
      "StartMarketingDate": "20110127",
      "MarketingCategoryName": "OTC MONOGRAPH NOT FINAL",
      "ApplicationNumber": "part333A",
      "LabelerName": "Ningbo Dowland Daily Health Co., Ltd",
      "SubstanceName": "ALCOHOL",
      "StrengthNumber": "62",
      "StrengthUnit": "g/100g",
      "Status": "Deprecated",
      "LastUpdate": "2015-02-06"
    },
    {
      "NDCCode": "75857-1001-0",
      "PackageDescription": "20 mL in 1 BOTTLE (75857-1001-0)",
      "NDC11Code": "75857-1001-00",
      "ProductNDC": "75857-1001",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Antibacterial Hand Sanitizer",
      "ProprietaryNameSuffix": "Citrus Scent",
      "NonProprietaryName": "Alcohol",
      "DosageFormName": "GEL",
      "RouteName": "TOPICAL",
      "StartMarketingDate": "20120705",
      "MarketingCategoryName": "OTC MONOGRAPH FINAL",
      "ApplicationNumber": "part333E",
      "LabelerName": "Ningbo Dowland Daily Health Co., Ltd",
      "SubstanceName": "ALCOHOL",
      "StrengthNumber": "62",
      "StrengthUnit": "mL/100mL",
      "Status": "Deprecated",
      "LastUpdate": "2015-02-06"
    }
  ]
}
                    

{"NDC":[{"NDCCode":"75857-2150-8","ProprietaryName":"Spf 15 Sunscreen","NonProprietaryName":"Octinoxate, Oxybenzone, Octisalate, Titanium Dioxide"},{"NDCCode":"75857-1100-8","ProprietaryName":"Antibactierial Hand Sanitizer","NonProprietaryName":"Ethyl Alcohol"},{"NDCCode":"75857-1105-8","ProprietaryName":"Antibactierial Hand Sanitizer","NonProprietaryName":"Ethyl Alcohol"},{"NDCCode":"75857-1108-8","ProprietaryName":"Antibacterial Hand Sanitizer","NonProprietaryName":"Ethyl Alcohol"},{"NDCCode":"75857-2101-8","ProprietaryName":"Spf30 Sunscreen","NonProprietaryName":"Octocrylene, Octinoxate, Oxybenzone, Oxybenzone"},{"NDCCode":"75857-9300-8","ProprietaryName":"Spf 30 Sunscreen","NonProprietaryName":"Octinoxate, Octisalate, Oxybenzone, Titanium Dioxide"},{"NDCCode":"0069-2150-30","ProprietaryName":"Caduet","NonProprietaryName":"Amlodipine Besylate And Atorvastatin Calcium"},{"NDCCode":"63874-201-01","ProprietaryName":"Propoxyphene And Acetaminophen","NonProprietaryName":"Propoxyphene Napsylate And Acetaminophen"},{"NDCCode":"63874-201-04","ProprietaryName":"Propoxyphene And Acetaminophen","NonProprietaryName":"Propoxyphene Napsylate And Acetaminophen"},{"NDCCode":"63874-201-30","ProprietaryName":"Propoxyphene And Acetaminophen","NonProprietaryName":"Propoxyphene Napsylate And Acetaminophen"},{"NDCCode":"63874-201-60","ProprietaryName":"Propoxyphene And Acetaminophen","NonProprietaryName":"Propoxyphene Napsylate And Acetaminophen"},{"NDCCode":"63874-201-90","ProprietaryName":"Propoxyphene And Acetaminophen","NonProprietaryName":"Propoxyphene Napsylate And Acetaminophen"},{"NDCCode":"68387-100-10","ProprietaryName":"Propoxyphene And Acetaminophen","NonProprietaryName":"Propoxyphene Napsylate And Acetaminophen"},{"NDCCode":"68387-100-12","ProprietaryName":"Propoxyphene And Acetaminophen","NonProprietaryName":"Propoxyphene Napsylate And Acetaminophen"},{"NDCCode":"68387-100-15","ProprietaryName":"Propoxyphene And Acetaminophen","NonProprietaryName":"Propoxyphene Napsylate And Acetaminophen"},{"NDCCode":"68387-100-30","ProprietaryName":"Propoxyphene And Acetaminophen","NonProprietaryName":"Propoxyphene Napsylate And Acetaminophen"},{"NDCCode":"68387-100-40","ProprietaryName":"Propoxyphene And Acetaminophen","NonProprietaryName":"Propoxyphene Napsylate And Acetaminophen"},{"NDCCode":"68387-100-50","ProprietaryName":"Propoxyphene And Acetaminophen","NonProprietaryName":"Propoxyphene Napsylate And Acetaminophen"},{"NDCCode":"68387-100-60","ProprietaryName":"Propoxyphene And Acetaminophen","NonProprietaryName":"Propoxyphene Napsylate And Acetaminophen"},{"NDCCode":"68387-100-90","ProprietaryName":"Propoxyphene And Acetaminophen","NonProprietaryName":"Propoxyphene Napsylate And Acetaminophen"},{"NDCCode":"71335-2150-1","ProprietaryName":"Buspirone Hydrochloride","NonProprietaryName":"Buspirone Hydrochloride"},{"NDCCode":"71335-2150-2","ProprietaryName":"Buspirone Hydrochloride","NonProprietaryName":"Buspirone Hydrochloride"},{"NDCCode":"71335-2150-3","ProprietaryName":"Buspirone Hydrochloride","NonProprietaryName":"Buspirone Hydrochloride"},{"NDCCode":"71335-2150-4","ProprietaryName":"Buspirone Hydrochloride","NonProprietaryName":"Buspirone Hydrochloride"},{"NDCCode":"71335-2150-5","ProprietaryName":"Buspirone Hydrochloride","NonProprietaryName":"Buspirone Hydrochloride"},{"NDCCode":"71335-2150-6","ProprietaryName":"Buspirone Hydrochloride","NonProprietaryName":"Buspirone Hydrochloride"},{"NDCCode":"75857-0001-0","ProprietaryName":"Antibacterial Wet Wipes","NonProprietaryName":"Benzalkonium Chloride"},{"NDCCode":"75857-0003-0","ProprietaryName":"Antibacterial Wet Wipes","NonProprietaryName":"Benzalkonium Chloride"},{"NDCCode":"75857-1000-2","ProprietaryName":"Antibacterial Hand Sanitizer - Citrus Scent","NonProprietaryName":"Ethyl Alcohol"},{"NDCCode":"75857-1001-0","ProprietaryName":"Antibacterial Hand Sanitizer","NonProprietaryName":"Alcohol"}]}
                    

<NDCList><NDC><NDCCode>75857-2150-8</NDCCode><ProprietaryName>Spf 15 Sunscreen</ProprietaryName><NonProprietaryName>Octinoxate, Oxybenzone, Octisalate, Titanium Dioxide</NonProprietaryName></NDC><NDC><NDCCode>75857-1100-8</NDCCode><ProprietaryName>Antibactierial Hand Sanitizer</ProprietaryName><NonProprietaryName>Ethyl Alcohol</NonProprietaryName></NDC><NDC><NDCCode>75857-1105-8</NDCCode><ProprietaryName>Antibactierial Hand Sanitizer</ProprietaryName><NonProprietaryName>Ethyl Alcohol</NonProprietaryName></NDC><NDC><NDCCode>75857-1108-8</NDCCode><ProprietaryName>Antibacterial Hand Sanitizer</ProprietaryName><NonProprietaryName>Ethyl Alcohol</NonProprietaryName></NDC><NDC><NDCCode>75857-2101-8</NDCCode><ProprietaryName>Spf30 Sunscreen</ProprietaryName><NonProprietaryName>Octocrylene, Octinoxate, Oxybenzone, Oxybenzone</NonProprietaryName></NDC><NDC><NDCCode>75857-9300-8</NDCCode><ProprietaryName>Spf 30 Sunscreen</ProprietaryName><NonProprietaryName>Octinoxate, Octisalate, Oxybenzone, Titanium Dioxide</NonProprietaryName></NDC><NDC><NDCCode>0069-2150-30</NDCCode><ProprietaryName>Caduet</ProprietaryName><NonProprietaryName>Amlodipine Besylate And Atorvastatin Calcium</NonProprietaryName></NDC><NDC><NDCCode>63874-201-01</NDCCode><ProprietaryName>Propoxyphene And Acetaminophen</ProprietaryName><NonProprietaryName>Propoxyphene Napsylate And Acetaminophen</NonProprietaryName></NDC><NDC><NDCCode>63874-201-04</NDCCode><ProprietaryName>Propoxyphene And Acetaminophen</ProprietaryName><NonProprietaryName>Propoxyphene Napsylate And Acetaminophen</NonProprietaryName></NDC><NDC><NDCCode>63874-201-30</NDCCode><ProprietaryName>Propoxyphene And Acetaminophen</ProprietaryName><NonProprietaryName>Propoxyphene Napsylate And Acetaminophen</NonProprietaryName></NDC><NDC><NDCCode>63874-201-60</NDCCode><ProprietaryName>Propoxyphene And Acetaminophen</ProprietaryName><NonProprietaryName>Propoxyphene Napsylate And Acetaminophen</NonProprietaryName></NDC><NDC><NDCCode>63874-201-90</NDCCode><ProprietaryName>Propoxyphene And Acetaminophen</ProprietaryName><NonProprietaryName>Propoxyphene Napsylate And Acetaminophen</NonProprietaryName></NDC><NDC><NDCCode>68387-100-10</NDCCode><ProprietaryName>Propoxyphene And Acetaminophen</ProprietaryName><NonProprietaryName>Propoxyphene Napsylate And Acetaminophen</NonProprietaryName></NDC><NDC><NDCCode>68387-100-12</NDCCode><ProprietaryName>Propoxyphene And Acetaminophen</ProprietaryName><NonProprietaryName>Propoxyphene Napsylate And Acetaminophen</NonProprietaryName></NDC><NDC><NDCCode>68387-100-15</NDCCode><ProprietaryName>Propoxyphene And Acetaminophen</ProprietaryName><NonProprietaryName>Propoxyphene Napsylate And Acetaminophen</NonProprietaryName></NDC><NDC><NDCCode>68387-100-30</NDCCode><ProprietaryName>Propoxyphene And Acetaminophen</ProprietaryName><NonProprietaryName>Propoxyphene Napsylate And Acetaminophen</NonProprietaryName></NDC><NDC><NDCCode>68387-100-40</NDCCode><ProprietaryName>Propoxyphene And Acetaminophen</ProprietaryName><NonProprietaryName>Propoxyphene Napsylate And Acetaminophen</NonProprietaryName></NDC><NDC><NDCCode>68387-100-50</NDCCode><ProprietaryName>Propoxyphene And Acetaminophen</ProprietaryName><NonProprietaryName>Propoxyphene Napsylate And Acetaminophen</NonProprietaryName></NDC><NDC><NDCCode>68387-100-60</NDCCode><ProprietaryName>Propoxyphene And Acetaminophen</ProprietaryName><NonProprietaryName>Propoxyphene Napsylate And Acetaminophen</NonProprietaryName></NDC><NDC><NDCCode>68387-100-90</NDCCode><ProprietaryName>Propoxyphene And Acetaminophen</ProprietaryName><NonProprietaryName>Propoxyphene Napsylate And Acetaminophen</NonProprietaryName></NDC><NDC><NDCCode>71335-2150-1</NDCCode><ProprietaryName>Buspirone Hydrochloride</ProprietaryName><NonProprietaryName>Buspirone Hydrochloride</NonProprietaryName></NDC><NDC><NDCCode>71335-2150-2</NDCCode><ProprietaryName>Buspirone Hydrochloride</ProprietaryName><NonProprietaryName>Buspirone Hydrochloride</NonProprietaryName></NDC><NDC><NDCCode>71335-2150-3</NDCCode><ProprietaryName>Buspirone Hydrochloride</ProprietaryName><NonProprietaryName>Buspirone Hydrochloride</NonProprietaryName></NDC><NDC><NDCCode>71335-2150-4</NDCCode><ProprietaryName>Buspirone Hydrochloride</ProprietaryName><NonProprietaryName>Buspirone Hydrochloride</NonProprietaryName></NDC><NDC><NDCCode>71335-2150-5</NDCCode><ProprietaryName>Buspirone Hydrochloride</ProprietaryName><NonProprietaryName>Buspirone Hydrochloride</NonProprietaryName></NDC><NDC><NDCCode>71335-2150-6</NDCCode><ProprietaryName>Buspirone Hydrochloride</ProprietaryName><NonProprietaryName>Buspirone Hydrochloride</NonProprietaryName></NDC><NDC><NDCCode>75857-0001-0</NDCCode><ProprietaryName>Antibacterial Wet Wipes</ProprietaryName><NonProprietaryName>Benzalkonium Chloride</NonProprietaryName></NDC><NDC><NDCCode>75857-0003-0</NDCCode><ProprietaryName>Antibacterial Wet Wipes</ProprietaryName><NonProprietaryName>Benzalkonium Chloride</NonProprietaryName></NDC><NDC><NDCCode>75857-1000-2</NDCCode><ProprietaryName>Antibacterial Hand Sanitizer - Citrus Scent</ProprietaryName><NonProprietaryName>Ethyl Alcohol</NonProprietaryName></NDC><NDC><NDCCode>75857-1001-0</NDCCode><ProprietaryName>Antibacterial Hand Sanitizer</ProprietaryName><NonProprietaryName>Alcohol</NonProprietaryName></NDC></NDCList>